This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: University of Pennsylvania, Vetigenics, Inc.. Active years: 2024.
Company Filing History:
1 out of 2,655 
1 out of 1 Years Active: 2024
Title: Innovations of Nicholas Chester in Canine Antibody Development.
Introduction
Nicholas Chester is an accomplished inventor based in Philadelphia, PA. He has made significant contributions to the field of veterinary medicine, particularly in the development of canine monoclonal antibodies.
Latest Patents
Nicholas Chester holds a patent for "Canine monoclonal antibodies against canine cytotoxic T lymphocyte associated protein 4 (CTLA-4)." This invention relates to canine antibodies, binding polypeptides, and scFvs that are specific for canine cytotoxic T lymphocyte associated protein 4 (CTLA-4). He has 1 patent to his name.
Career Highlights
Throughout his career, Nicholas has worked with notable institutions, including the University of Pennsylvania and Vetigenics, Inc. His work has focused on advancing the understanding and treatment of canine diseases through innovative antibody therapies.
Collaborations
Nicholas has collaborated with esteemed colleagues such as Nicola Mason and Donald L. Siegel. Their combined expertise has contributed to the success of his research and innovations.
Conclusion
Nicholas Chester's work in developing canine monoclonal antibodies represents a significant advancement in veterinary medicine. His contributions continue to impact the field positively.